Apellis Pharmaceuticals Inc (NAS:APLS)
$ 40.535 0.855 (2.15%) Market Cap: 4.94 Bil Enterprise Value: 4.60 Bil PE Ratio: 0 PB Ratio: 18.50 GF Score: 38/100

Apellis Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 11, 2023 / 02:00PM GMT
Release Date Price: $41.51 (-0.17%)
Unidentified Analyst

Good morning, everyone. I'll just read this research disclosure. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Well, welcome, Cedric and Tim, fantastic to have you, and congratulations in terms of product approval and launch.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Thank you.

Questions & Answers

Unidentified Analyst

Before maybe jumping into some granularity in terms of what's been happening over the past couple of months, it'd be great just to spend 2 minutes on the background of the company, and then we'll dive in on SYFOVRE.

Cedric Francois
Apellis Pharmaceuticals, Inc. - Co-Founder, President, CEO & Director

Yes. Thank you so

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot